<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Preoperative CA-125 Values as a Predictive Factor for the Postoperative Outcome in Primary Serous Ovarian Cancer</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>Dr. med. Dr. (syr.</roleName><forename type="first">Zelal</forename><surname>Mustafa</surname></persName>
						</author>
						<author>
							<persName><surname>Muallem</surname></persName>
						</author>
						<author role="corresp">
							<persName><forename type="first">Mustafa</forename><surname>Zelal Muallem</surname></persName>
							<email>zelal.muallem@charite.de</email>
							<affiliation key="aff1">
								<orgName type="department">Department of Gynecology</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Asya</forename><surname>Parashkevova</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Ovarian Cancer Tumor Bank</orgName>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Virchow Campus Clinic</orgName>
								<orgName type="institution" key="instit2">Charité Medical University</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jumana</forename><surname>Almuheimid</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Gynecology</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rolf</forename><surname>Richter</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Gynecology</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yasser</forename><surname>Diab</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Gynecology</orgName>
								<orgName type="institution">Portland District Hospital</orgName>
								<address>
									<settlement>Victoria</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elena</forename><forename type="middle">Ioana</forename><surname>Braicu</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Gynecology</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">Ovarian Cancer Tumor Bank</orgName>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Virchow Campus Clinic</orgName>
								<orgName type="institution" key="instit2">Charité Medical University</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jalid</forename><surname>Sehouli</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Gynecology</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution">Charité University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum, Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Preoperative CA-125 Values as a Predictive Factor for the Postoperative Outcome in Primary Serous Ovarian Cancer</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">C7356D8B969741B430FE143919C1E488</idno>
					<idno type="DOI">10.21873/anticanres.11674</idno>
					<note type="submission">Received April 26, 2017 Revised May 3, 2017 Accepted May 8, 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:42+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Ovarian cancer</term>
					<term>CA-125</term>
					<term>primary cytoreductive surgery</term>
					<term>complete tumor resection</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background/Aim: The purpose of the study was to examine the preoperative CA-125 values as a predictive factor for postoperative outcome in primary serous ovarian cancer (POC) for complete tumor resection (CTR)  and evaluate the preoperative CA-125 levels with other vital clinical dynamics such as ascites, lymph node involvement, diffuse peritoneal carcinomatosis, grading and staging.</s><s>Patients and Methods: A cohort of 277 POC-patients aged 18-75 years, who had undergone primary cytoreductive surgery at the Department of Gynecology &amp; Oncological Surgery, Charité, Campus Virchow  Klinikum (CVK)  between 2000 und 2009 was analyzed in correlation with the preoperative CA-125 values.</s><s>Results: The median preoperative CA-125 value in high-grade serous POC patients was 636 U/ml (204-2312 U/ml) compared to 284 U/ml (148.5-1,378</s><s>U/ml) in low-grade serous POC patients (p=0.016).</s><s>For the survival analyses both the cut-off values 252 and 475 U/ml, with highest sum from sensitivity (79.1% and 65.9%, respectively) and specificity (41.9% and 55.1%,  respectively), were used to compare the relationship between preoperative CA-125 levels and (CTR), progression-free (PFS) and overall survival (OS).</s><s>There was no significant difference between PFS and OS in three different groups of patients (preoperative CA-125 levels &lt;252 U/ml, CA 125 levels between 252-475 U/ml and &gt;475 U/ml).</s><s>Conclusion: Preoperative CA-125 is a poor, but statistically significant predictive factor for CTR after PCS.</s><s>Preoperative CA-125 can predict neither the progression-free nor overall survival for POC patients.</s></p><p><s>Epithelial ovarian cancer (EOC) is the seventh most common cancer worldwide, with 238,700 new cases and 151,900 deaths in 2012 (1).</s><s>It remains the major cause of death from gynecologic malignancies and represents the fifth leading cause of all cancer-deaths among women (2).</s></p><p><s>CA-125 is a repeating peptide epitope of mucin (MUC) 16 (3-4), which promotes cancer cell proliferation and inhibits anti-cancer immune responses (5-6).</s><s>This and published evidence pointing to an altered expression of the protein in ovarian cancers ( <ref type="formula">7</ref>) have spurred the interest on CA-125 as a biomarker for serous ovarian cancer (8).</s><s>Numerous research studies have investigated the role of preoperative CA-125 value as predictor for postoperative outcome: some of them reviewed only patients with epithelial ovarian cancer (2, 9), or the predictive value of preoperative CA-125 together with preoperative computed tomography scan (CT) in patient groups with advanced ovarian, fallopian tube and peritoneal cancer disease (10).</s><s>However, the predictive value of CA-125 levels has been inconclusive (11), therefore research has also focused on another tumor marker like Human epididymal protein 4 (HE4) in serum plasma in order to predict the surgical outcome in Primary ovarian cancer (POC) patients ( <ref type="formula">12</ref>).</s></p><p><s>The objective aim of our retrospective study was to examine the predictive value of preoperative CA-125 for optimal cytoreduction and postoperative overall survival after primary cytoreductive surgery (PCS) and evaluate the preoperative CA-125 levels with other vital clinical dynamics such as ascites, lymph node involvement, diffuse peritoneal carcinomatosis, grading and staging.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and Methods</head><p><s>The database from the Tumor Bank Ovarian Cancer (www.tocnetwork.de)</s><s>was utilized to identify patients with the required specific case history.</s><s>This database, essentially, a prospective documentation tool includes clinical data, disease history, tumor spread, presence of ascites, and presence and location of residual tumor mass intra-operatively obtained through an interview with the 3157</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>surgeon immediately post-operatively.</s><s>The study had in place the requisite informed consent before collection of the clinical data and the ethics committee approval from Charité local Ethics Committee (EK207/2003).</s><s>Cancer staging in the study was based on The International Federation of Gynecology and Obstetrics (FIGO) classification prior to 2014 to match the database <ref type="bibr" target="#b12">(13)</ref>.</s><s>The optimal surgery was defined as no macroscopic tumor residual after PCS.</s></p><p><s>We included all serous POC-patients aged 18-75 years, which underwent PCS at the department of Gynecology with oncological surgery, Charité, Campus Virchow Klinikum (CVK) between 2000 and 2009.</s><s>The design had an exclusion criterion of patients with non-epithelial ovarian cancer, other histologies than serous, patients with no preoperative CA-125 evaluations, women who had undergone interval surgery, and those who were treated for another malignant disease in the last 5 years of the study period.</s></p><p><s>The statistical analysis has been performed at the Charité Medical University Berlin.</s><s>All analyses have been performed by IBM SPSS Statistics 22.0 (SPSS, Chicago, IL, USA).</s></p><p><s>Descriptive statistic tests were used to characterize the patient cohort and Kolmogorov Simirnov test to characterize the distribution of preoperative CA-125 levels.</s></p><p><s>With Receiving operating characteristic (ROC) analysis sensitivity and specificity were calculated to define the optimal cutoff value of the preoperative CA-125 levels for predicting Complete tumor resection (CTR).</s></p><p><s>The correlation between preoperative CA-125 levels and clinical factors such as age, ascites, FIGO stage and CTR was investigated using non-parametric univariate tests such as Kendall-Tau b, Spearman Rho, Man-Whitney and Kruskal Wallis test.</s></p><p><s>Median and 95% confidence intervals (95%CI) of Progression free survival (PFS) and Overall survival (OS) were estimated according to the Kaplan-Meier method.</s><s>PFS was defined as the length of time between the end of the last chemotherapy cycle to the occurrence of the relapse.</s><s>OS was determined as the length of time between the date of first diagnosis and the date of death or end of follow-up.</s><s>Log-rank test statistics for analysis of the equality of survival distribution were performed.</s><s>Statistical significance was defined by p&lt;0.05 and two-sided tests were applied.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>The patient characteristics are presented in Table <ref type="table" target="#tab_0">I</ref>.</s><s>A total of 227 patients in a POC cohort were investigated and CA-125 measured before the primary cytoreductive surgery in all patients.</s><s>The median age of the cohort at the first diagnosis was 59 years.</s><s>One in four patients was younger than 50 or older than 65 years.</s><s>A percentage of 96.9% of them had an advanced recurrent POC (FIGO III-IV).</s><s>A high-grade serous POC had been diagnosed in 64.5% of cases, with 81.5% of the patients with ascites (44.1% with less than 500 ml and 37.4% with more than 500 ml).</s><s>A percentage of 59.9% of the women had been operated with no macroscopic tumor residual and 85.5% of the operated women had undergone some type of lymph node dissection.</s><s>A percentage of 55.5% of them have had pelvic and/or paraaortal lymph node metastasis at the time of operation.</s><s>The median follow-up time was 44.4 months (range=0.1-158</s><s>months).</s><s>The main CA-125 value was 1991.9; the median was 552 U/ml (the interquartile range=IQR: 164-2,004 U/ml).</s><s>The median preoperative CA-125 value in highgrade serous POC patients was 636 U/ml (range=204-2,312 U/ml) compared to 284 U/ml (range=148.5-1,378</s><s>U/ml) in low-grade serous POC patients (p=0.016).</s><s>Kolmogorov-Smirnov Test does not display normal distribution of CA-125 in the cohort (Figure <ref type="figure" target="#fig_0">1-A</ref>) whereas, the logarithmic conversed CA-125 values illustrate a normal, symmetric distribution curve (Figure <ref type="figure" target="#fig_0">1-B</ref>).</s></p><p><s>The correlation between preoperative CA-125 levels and the outcomes of surgery (CTR).</s><s>Since, the Area Under Curve (AUC) has a small surface, to predict the prognostic value of preoperative CA-125; it was prudent to set a cut-off value of preoperative CA-125, which predicts the CTR.</s><s>Thus, the estimated optimal CA-125 preoperative cut-off value in our study was 252 U/ml and 475 U/ml with highest sum from sensitivity (79.1% and 65.9%, respectively) and specificity (41.9% and 55.1%, respectively) (together, namely 121), so that we could predict the chance for CTR for 79.1% of patients, who had CA-125 less than 252 U/ml before the primary cytoreductive surgery and for 65.9% of patients with preoperative CA-125 of less than 475 U/ml.</s></p><p><s>The correlation between preoperative CA-125 levels and PFS or OS.</s><s>For the survival analyses both the cut off values 252 and 475 U/ml were used to compare the relationship between preoperative CA-125 levels and PFS or OS.</s><s>There was no significant difference between PFS and OS in three different groups of patients (preoperative CA-125 levels &lt;252 U/ml, CA-125 levels between 252-475 U/ml and &gt;475 U/ml) (Figure <ref type="figure" target="#fig_1">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>One of the statistically significant cut-off values using ROC analysis of preoperative CA-125 levels in the study has been 475 U/ml with best sensitivity (65.9%) and specificity (55.1%).</s><s>The value matches with other similar studies that have reported that an optimal cytoreduction (defined here as with residual tumor less than 1 cm) could be predicted only in 50% of cases with FIGO III-staged epithelial POC using a cut off value of preoperative CA-125 of 500 U/ml.</s><s>The study has also elucidated that the chance of an optimal cytoreduction decreases with higher values of preoperative CA-125 <ref type="bibr" target="#b13">(14)</ref>.</s><s>These results fall in tandem with studies of Mury et al. <ref type="bibr" target="#b14">(15)</ref> that have analyzed the prognostic and predictive values of CA-125 serum concentrations before and after surgery as well as their correlation with clinicopathological variables in a collective of 231 patients with POC (with different histological subtypes).</s><s>Despite of correlation with some surgical results, they could not determine a preoperative cutoff value for prediction of the surgical result.</s><s>A prognostic relevance was only observed for postoperative CA-125 in stage III/IV patients.</s></p><p><s>The study also falls in line with the study of Memarzadeh et al. <ref type="bibr" target="#b8">(9)</ref> in 99 patients with stage IIIC and IV epithelial POC aiming to test the utility of preoperative CA-125 to predict optimal primary tumor cytoreduction (defined here as largest volume of residual disease &lt;1 cm in maximal dimension).</s><s>Optimal cytoreduction was achieved in 73% of patients with a mean CA-125 level of 569 U/ml, while among patients with suboptimal cytoreduction the mean CA-125 level was 1520 U/ml (p&lt;0.007).</s><s>With a CA-125 level of 912 U/ml identified as the optimal cut-point to distinguish the two groups, the sensitivity of the test in predicting optimal cytoreduction has been just 58% (in tandem with 79.1% and 65.9%, respectively for our both cutoff values 252 and 475 U/ml in present study) and the specificity 54% leading us to the conclusion that CA-125 level is a weak positive and negative predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer.</s></p><p><s>Similar study by <ref type="bibr">Chi et al. (16)</ref> have also concluded that preoperative CA-125 does not predict the primary cytoreductive outcome of patients with advanced ovarian, tubal, or peritoneal carcinoma.</s><s>However, with a preoperative CA-125 &gt;500 U/ml, extensive upper abdominal procedures were necessary in 50% of cases to achieve residual disease ≤1 cm.</s><s>Interestingly, CTR was achieved only in 25% of their collective.</s></p><p><s>Harter et al. <ref type="bibr" target="#b16">(17)</ref> reviewed prognostic factors for CTR after first-and second-line ovarian cancer.</s><s>They could not find sufficient predictive markers (including the preoperative CA-125) for CTR.</s></p><p><s>In the European multi-centric project "Ovarian Cancer: Diagnosis of a silent killer" (OVCAD) <ref type="bibr" target="#b11">(12)</ref>, 275 consecutive patients with POC were enrolled and analyzed.</s><s>The results showed that the combination of HE4 and CA-125 expression in plasma might predict the surgical outcome in EOC which may have a prognostic impact on PFS and OS.</s><s>Plasma CA-125 and the risk index (HE4 and CA-125) were independent predictive factors for surgical outcome (p=0.001,</s><s>OR=3.37, 95%CI=1.61-7.06 and p&lt;0.001,</s><s>OR=6.041, 95% CI=2.33-15.65,</s><s>respectively).</s></p><p><s>Limiting factors of this study were the retrospective design, and the FIGO classifications provided were defined according to the old classification system.</s><s>Nevertheless, our study has convincing advantages.</s><s>The study cohort was restricted to patients with serous POC, thus only patients where preoperative CA-125 values assumed to be reflecting the peritoneal dissemination of cancer were included.</s><s>In addition, the rather high number of patients in this collective, the high rate of CTR and the long median follow-up period add more value to our results.</s></p><p><s>In conclusion, preoperative CA-125 is poor, but statistically significant predictive factor for CTR after PCS.</s><s>Preoperative CA-125 can predict neither the progression-free nor the overall survival for POC patients.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>The distribution of CA-125 values in our collective.</s><s>A: Kolmogorov-Smirnov Test with normal distribution.</s><s>B: Logarithmic conversed CA-125 values with symmetric curve of distribution.</s></p></div></figDesc><graphic coords="3,67.96,85.11,481.92,251.76" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Progression-free and overall survival in the 3 groups of primary serous ovarian cancer patients according to preoperative CA-125 values.</s></p></div></figDesc><graphic coords="3,66.09,374.75,481.92,240.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table I .</head><label>I</label><figDesc><div><p><s>Characteristics of 227 primary serous ovarian cancer patients underwent primary cytoreductive surgery in Charité Berlin.</s></p></div></figDesc><table><row><cell>Characteristics</cell><cell>All patients n=227 (%)</cell></row><row><cell>Age at first diagnosis [years] CA-125 FIGO classification II III IV Grading 1-2 3 Ascites No ascites &lt;500 ml &gt;500 ml Residual tumour No residual &lt;10 mm ≥10 mm Lymph nodes status N0 N1 Nx</cell><cell>Median 59 (21-92) 552 U/mL (11-38 387) 7 (3.1%) 178 (78.4%) 42 (18.5%) 80 (35.2%) 147 (64.8%) 42 (18.5%) 100(44.1%) 85 (37.4%) 136 (59.9%) 64 (28.2%) 27 (11.9%) 68 (30%) 126 (55.5%) 33 (14.5%)</cell></row></table></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflicts of Interest</head><p><s>The Authors declare in financial or personal conflict of interest.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Global Cancer Statistics</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Torre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Siegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lortet-Tieulent</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CA Cancer J Clin</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="87" to="108" />
			<date type="published" when="2012">2012. 2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls</title>
		<author>
			<persName><forename type="first">I</forename><surname>Díaz-Padilla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Razak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Minig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Q</forename><surname>Bernardini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">María</forename><surname>Del Campo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Transl Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="15" to="20" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">The CA 125 gene: an extracellular superstructure dominated by repeat sequences</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>O'brien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Beard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Underwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Dennis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Santin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>York</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">ANTICANCER RESEARCH</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="3157" to="3161" />
			<date type="published" when="2001">2001. 2017</date>
		</imprint>
	</monogr>
	<note>Tumour Biol</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Molecular cloning of the ca125 ovarian cancer antigen identification as a new mucin, muc16</title>
		<author>
			<persName><forename type="first">Yin</forename><surname>Bw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lloyd</forename><surname>Ko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">276</biblScope>
			<biblScope unit="issue">29</biblScope>
			<biblScope unit="page" from="27371" to="27375" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Bast</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Spriggs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="429" to="430" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Down-regulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Comamala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pinard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Theriault</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Matte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Albert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boivin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Beaudin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Piche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rancourt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="989" to="999" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells</title>
		<author>
			<persName><forename type="first">S</forename><surname>Bafna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kaur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Batra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="2893" to="2904" />
			<date type="published" when="2010">20. 2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Ovarian cancer biomarkers for molecular biosensors and translational medicine</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Suh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Castro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Blake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Goy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Rev Mol Diagn</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1069" to="1083" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">CA 125 levels are weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Memarzadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Berek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Farias-Eisner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Gynecol Cancer</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="120" to="124" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimalcytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Suidan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">T</forename><surname>Ramirez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Sarasohn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Teitcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mironov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Iyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Iasonos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hosaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Aghajanian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Leitao</surname></persName>
		</author>
		<author>
			<persName><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Gardner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Abu-Rustum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sonoda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hricak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chi</forename><surname>Ds</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="455" to="461" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Preventive Services Task Force: Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename><surname>Moyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">157</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="900" to="904" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients. Results from the OVCAD study</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">I</forename><surname>Braicu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fotopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Van Gorp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Richter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Chekerov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Butz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Castillo-Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mahner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zeillinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Concin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Vergote</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sehouli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="245" to="251" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Staging Announcement: FIGO Cancer Committee Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page">383</biblScope>
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Chi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Venkatraman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Masson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Hoskins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="227" to="231" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Prognostic and predictive relevance of CA.125 at primary surgery of ovarian cancer</title>
		<author>
			<persName><forename type="first">D</forename><surname>Mury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Woelber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Eulenburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Choschzick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Witzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schwarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jaenicke</forename></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mahner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cancer Res Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1131" to="1137" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Chi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Zivanovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Palayekar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Eisenhauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Abu-Rustum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sonoda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Leitao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Barakat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="6" to="10" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Prognostic factors for complete debulking in first-and second-line ovarian cancer</title>
		<author>
			<persName><forename type="first">P</forename><surname>Harter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hilpert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mahner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kommoss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Heitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pfisterer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Du Bois</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Gynecol Cancer</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="14" to="17" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
